Sleep and Diurnal Rest-Activity Rhythm Disturbances in a Mouse Model of Alzheimer's Disease

Abstract

Study ObjectivesAccumulating evidence suggests a strong association between sleep, amyloid-beta (A{beta}) deposition, and Alzheimers disease (AD). We sought to determine if: (1) deficits in rest-activity rhythms and sleep are significant phenotypes in J20 AD mice, (2) metabotropic glutamate receptor 5 inhibitors (mGluR5) could rescue deficits in rest-activity rhythms and sleep, and (3) A{beta} levels are responsive to treatment with mGluR5 inhibitors. MethodsDiurnal rest-activity levels were measured by actigraphy and sleep-wake patterns by electroencephalography (EEG), while animals were chronically treated with mGluR5 inhibitors. Behavioral tests were performed, and A{beta} levels measured in brain lysates. ResultsJ20 mice exhibited a 4.5 hour delay in the acrophase of activity levels compared to wild-type littermates, and spent less time in REM sleep during the second half of the light period. J20 mice also exhibited decreased NREM delta power but increased NREM sigma power. The mGluR5 inhibitor CTEP rescued the REM sleep deficit and improved NREM delta and sigma power but did not correct rest-activity rhythms. No statistically significant differences were observed in A{beta} levels, rotarod performance or the passive avoidance task following chronic mGluR5 inhibitor treatment. ConclusionsJ20 mice have disruptions in rest-activity rhythms and reduced homeostatic sleep pressure (reduced NREM delta power). NREM delta power was increased following treatment with an mGluR5 inhibitor. Drug bioavailability was poor. Further work is necessary to determine if mGluR5 is a viable target for treating sleep phenotypes in AD. Statement of SignificanceSleep disruption is evolving as an important risk factor as well as phenotype of neurological diseases including Alzheimers disease. This study is novel in determining alterations in the rest-activity rhythm and sleep-wake pattern of J20 Alzheimers disease mice and wild type littermates. Specifically, there is a delay in acrophase with prolonged hyperactivity during the dark cycle, and reduced sleep pressure that was improved by treatment with mGluR5 inhibitor. Critical remaining knowledge gaps and future directions include testing the effects of Alzheimers disease drugs on rescue of sleep and rest-activity patterns in other Alzheimers disease models. These studies are relevant to human Alzheimers disease as monitoring sleep phenotypes may predict disease risk, and therapies that normalize sleep patterns may slow progression.